Clinical Trial Update: A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy [Phase 3]

View source ↗

Summary

Phase 3 trial of atezolizumab as adjuvant therapy for high-risk renal cell carcinoma after nephrectomy was terminated; results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Atezolizumab (atezolizumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Renal Cell Carcinoma | Phase 3 | Status: TERMINATED | Results posted: 2023-08-03